WO2003016480A3 - Tgf-$g(a) polypeptides, functional fragments and methods of use therefor - Google Patents

Tgf-$g(a) polypeptides, functional fragments and methods of use therefor Download PDF

Info

Publication number
WO2003016480A3
WO2003016480A3 PCT/US2002/026023 US0226023W WO03016480A3 WO 2003016480 A3 WO2003016480 A3 WO 2003016480A3 US 0226023 W US0226023 W US 0226023W WO 03016480 A3 WO03016480 A3 WO 03016480A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tgf
polypeptides
functional fragments
use therefor
Prior art date
Application number
PCT/US2002/026023
Other languages
French (fr)
Other versions
WO2003016480A2 (en
Inventor
Daniel R Twardzik
Andre Pernet
Thomas S Felker
Stefan Paskell
Original Assignee
Stem Cell Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell Pharmaceuticals Inc filed Critical Stem Cell Pharmaceuticals Inc
Priority to AU2002336355A priority Critical patent/AU2002336355A1/en
Publication of WO2003016480A2 publication Critical patent/WO2003016480A2/en
Publication of WO2003016480A3 publication Critical patent/WO2003016480A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed are TGF-α polypetides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex-vivo and in vivo applications.
PCT/US2002/026023 2001-08-17 2002-08-16 Tgf-$g(a) polypeptides, functional fragments and methods of use therefor WO2003016480A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002336355A AU2002336355A1 (en) 2001-08-17 2002-08-16 Tgf-$g(a) polypeptides, functional fragments and methods of use therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/932,172 2001-08-17
US09/932,172 US6815418B2 (en) 1999-08-19 2001-08-17 TGF-α polypeptides, functional fragments and methods of use therefor

Publications (2)

Publication Number Publication Date
WO2003016480A2 WO2003016480A2 (en) 2003-02-27
WO2003016480A3 true WO2003016480A3 (en) 2004-11-11

Family

ID=25461892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/026023 WO2003016480A2 (en) 2001-08-17 2002-08-16 Tgf-$g(a) polypeptides, functional fragments and methods of use therefor

Country Status (3)

Country Link
US (1) US6815418B2 (en)
AU (1) AU2002336355A1 (en)
WO (1) WO2003016480A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795202B2 (en) 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
AU743251B2 (en) * 1997-08-04 2002-01-24 Regents Of The University Of California, The Methods for treating neurological deficits
US20010007657A1 (en) * 1997-08-04 2001-07-12 Reid James Steven Compositions and methods for manipulating glial progenitor cells and treating neurological deficits
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
JP2003522131A (en) * 1999-08-19 2003-07-22 ステム セル ファーマシューティカルズ，インコーポレーテッド TGF-α polypeptides, functional fragments and uses thereof
US7838292B1 (en) * 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
US9549895B2 (en) * 2004-04-23 2017-01-24 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20060184251A1 (en) * 2005-01-07 2006-08-17 Zongtao Zhang Coated medical devices and methods of making and using
CA2590338A1 (en) 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
WO2006128125A2 (en) * 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
US20080069854A1 (en) * 2006-08-02 2008-03-20 Inframat Corporation Medical devices and methods of making and using
CN101588826A (en) * 2006-08-02 2009-11-25 英孚拉玛特公司 Lumen-supporting devices and methods of making and using
US20100034808A1 (en) * 2006-11-21 2010-02-11 Toru Nakazawa Compositions and methods for preserving cells of the eye

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4863899A (en) 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
ATE85080T1 (en) 1984-02-17 1993-02-15 Genentech Inc HUMAN TRANSFORMATIONAL GROWTH FACTOR AND PRECURSORS OR FRAGMENTS THEREOF, CELLS, DNA, VECTORS AND METHODS FOR THEIR PRODUCTION, COMPOSITIONS AND PRODUCTS CONTAINING THEM, AND ANTIBODIES AND DIAGNOSTIC METHODS DERIVED THEREOF.
US4749683A (en) 1985-01-25 1988-06-07 President And Fellows Of Harvard College Inhibition of gastric acid secretion with alpha-transforming growth factor
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4874746A (en) 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5102870A (en) 1989-04-14 1992-04-07 Schering Ag Treatment and prevention of oral mucositis with growth factors
US5229493A (en) 1990-10-26 1993-07-20 Children's Medical Center Corporation Smooth muscle mitogen
JPH04352800A (en) 1990-10-26 1992-12-07 Childrens Medical Center Corp:The Smooth muscle mitogen
US5886141A (en) 1990-10-26 1999-03-23 Takeda Chemical Industries, Ltd. Smooth muscle mitogen peptides and DNA coding therefor
US5604202A (en) 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5980885A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US6071889A (en) 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US5981165A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US6558952B1 (en) 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
DE69433661T2 (en) 1993-01-29 2005-02-10 Neurospheres Holding Ltd., Calgary GENETIC MODIFICATION OF NEURAL STEM CELLS
ATE231727T1 (en) 1995-11-09 2003-02-15 Takeda Chemical Industries Ltd COMPOSITION FOR IMPROVEMENT OF PANCREAS FUNCTION
US5814308A (en) 1996-03-26 1998-09-29 Zhang; Ke Methods for the treatment of gastrointestinal tract disorders
EP0941109A1 (en) 1996-11-15 1999-09-15 Neurospheres Holdings Ltd. Pretreatment with growth factors to protect against cns damage
AU5530198A (en) 1996-12-16 1998-07-15 Zymogenetics Inc. Compositions and methods for stimulating pancreatic islet cell regeneration
AU743251B2 (en) 1997-08-04 2002-01-24 Regents Of The University Of California, The Methods for treating neurological deficits
EP1175487A2 (en) 1999-02-10 2002-01-30 Curis, Inc. Pancreatic progenitor cells, methods and uses related thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand

Also Published As

Publication number Publication date
AU2002336355A1 (en) 2003-03-03
US20020169119A1 (en) 2002-11-14
WO2003016480A2 (en) 2003-02-27
US6815418B2 (en) 2004-11-09

Similar Documents

Publication Publication Date Title
WO2003016480A3 (en) Tgf-$g(a) polypeptides, functional fragments and methods of use therefor
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
WO2004012759A3 (en) Use of erythropoietin
WO2003033192A3 (en) Process for the production of sintered porous bodies
WO2001001748A3 (en) Peptide compounds that bind her2
WO2006089001A3 (en) Lentiviral vectors and their use
WO2006044359A3 (en) Heterocyclic aromatic compounds useful as growth hormone secretagogues
WO2005063809A8 (en) Nature-identical erythropoietin
WO2001051520A3 (en) Nogo receptor-mediated blockade of axonal growth
WO1998049300A3 (en) Truncated vegf-related proteins
EP2301563A3 (en) HSP20 peptides
WO2002078614A3 (en) Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
WO2007060213A3 (en) Erythropoietin polypeptides and uses thereof
WO2002097030A3 (en) Peptides derived from neural thread proteins and their medical use
WO2003014151A3 (en) Human secreted proteins, their encoding polynucleotides, and uses thereof
WO2004031367A3 (en) Uses of human zven proteins and polynucleotides
WO2003040296A3 (en) Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2003031572A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2001012127A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
WO2001031008A3 (en) Human and rat fgf-20 genes and gene expression products
WO2003046180A3 (en) Human cdnas and proteins and uses thereof
WO2003039484A3 (en) Novel compositions and methods for cancer
EP2075346A3 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
UA84831C2 (en) Coagulation factor vii derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

Kind code of ref document: A2

Designated state(s): AU CA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP